Cargando…
Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors
BACKGROUND: Malignant tumors of the musculoskeletal system, especially osteosarcoma, Ewing sarcoma and rhabdomyosarcoma, pose a major threat to the lives and health of adolescents and children. Current treatments for musculoskeletal tumors mainly include surgery, chemotherapy, and radiotherapy. The...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866880/ https://www.ncbi.nlm.nih.gov/pubmed/33546657 http://dx.doi.org/10.1186/s12891-021-04020-2 |
_version_ | 1783648176094314496 |
---|---|
author | Liu, Wei Wang, Shubin Lin, Binhui Zhang, Wei Ji, Guangrong |
author_facet | Liu, Wei Wang, Shubin Lin, Binhui Zhang, Wei Ji, Guangrong |
author_sort | Liu, Wei |
collection | PubMed |
description | BACKGROUND: Malignant tumors of the musculoskeletal system, especially osteosarcoma, Ewing sarcoma and rhabdomyosarcoma, pose a major threat to the lives and health of adolescents and children. Current treatments for musculoskeletal tumors mainly include surgery, chemotherapy, and radiotherapy. The problems of chemotherapy resistance, poor long-term outcome of radiotherapy, and the inherent toxicity and side effects of chemical drugs make it extremely urgent to seek new treatment strategies. MAIN TEXT: As a potent gene editing tool, the rapid development of CRISPR/Cas9 technology in recent years has prompted scientists to apply it to the study of musculoskeletal tumors. This review summarizes the application of CRISPR/Cas9 technology for the treatment of malignant musculoskeletal tumors, focusing on its essential role in the field of basic research. CONCLUSION: CRISPR, has demonstrated strong efficacy in targeting tumor-related genes, and its future application in the clinical treatment of musculoskeletal tumors is promising. |
format | Online Article Text |
id | pubmed-7866880 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78668802021-02-08 Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors Liu, Wei Wang, Shubin Lin, Binhui Zhang, Wei Ji, Guangrong BMC Musculoskelet Disord Review BACKGROUND: Malignant tumors of the musculoskeletal system, especially osteosarcoma, Ewing sarcoma and rhabdomyosarcoma, pose a major threat to the lives and health of adolescents and children. Current treatments for musculoskeletal tumors mainly include surgery, chemotherapy, and radiotherapy. The problems of chemotherapy resistance, poor long-term outcome of radiotherapy, and the inherent toxicity and side effects of chemical drugs make it extremely urgent to seek new treatment strategies. MAIN TEXT: As a potent gene editing tool, the rapid development of CRISPR/Cas9 technology in recent years has prompted scientists to apply it to the study of musculoskeletal tumors. This review summarizes the application of CRISPR/Cas9 technology for the treatment of malignant musculoskeletal tumors, focusing on its essential role in the field of basic research. CONCLUSION: CRISPR, has demonstrated strong efficacy in targeting tumor-related genes, and its future application in the clinical treatment of musculoskeletal tumors is promising. BioMed Central 2021-02-05 /pmc/articles/PMC7866880/ /pubmed/33546657 http://dx.doi.org/10.1186/s12891-021-04020-2 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Liu, Wei Wang, Shubin Lin, Binhui Zhang, Wei Ji, Guangrong Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors |
title | Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors |
title_full | Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors |
title_fullStr | Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors |
title_full_unstemmed | Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors |
title_short | Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors |
title_sort | applications of crispr/cas9 in the research of malignant musculoskeletal tumors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866880/ https://www.ncbi.nlm.nih.gov/pubmed/33546657 http://dx.doi.org/10.1186/s12891-021-04020-2 |
work_keys_str_mv | AT liuwei applicationsofcrisprcas9intheresearchofmalignantmusculoskeletaltumors AT wangshubin applicationsofcrisprcas9intheresearchofmalignantmusculoskeletaltumors AT linbinhui applicationsofcrisprcas9intheresearchofmalignantmusculoskeletaltumors AT zhangwei applicationsofcrisprcas9intheresearchofmalignantmusculoskeletaltumors AT jiguangrong applicationsofcrisprcas9intheresearchofmalignantmusculoskeletaltumors |